Reposal

Nowadays, Reposal has become a topic of great importance in today's society. With the advancement of technology and rapid globalization, Reposal has become an increasingly relevant topic of discussion in different areas. Whether in the social, political, economic or environmental sphere, Reposal represents a turning point that has marked a before and after in the way in which society develops. In this article, we will explore different aspects related to Reposal, from its impact on people's daily lives to its influence on the global landscape.

Reposal
Clinical data
Other namesReposamal, 5-Ethyl-5-(bicyclo(3.2.1)octenyl)barbituric acid
ATC code
Identifiers
  • 5-bicyclooct-2-en-3-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H18N2O3
Molar mass262.309 g·mol−1
3D model (JSmol)
  • O=C1NC(=O)NC(=O)C1(CC)C=3C2C(CC2)C=3
  • InChI=1S/C14H18N2O3/c1-2-14(11(17)15-13(19)16-12(14)18)10-6-8-3-4-9(5-8)7-10/h6,8-9H,2-5,7H2,1H3,(H2,15,16,17,18,19)/t8-,9+/m0/s1 checkY
  • Key:MKELYWOVSPVORM-DTWKUNHWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.

References

  1. ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. I. Pharmacodynamic Activity". Ugeskrift for Laeger (in Danish). 125: 1735–8. PMID 14103836.
  2. ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. Ii. Clinical Effects". Ugeskrift for Laeger (in Danish). 125: 1739–41. PMID 14103837.
  3. ^ Nielsen P, Tarding F (1968). "The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal)". Acta Pharmacologica et Toxicologica. 26 (6): 521–30. doi:10.1111/j.1600-0773.1968.tb00471.x. PMID 5756387.